1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Cimzia (certolizumab pegol) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

Cimzia (certolizumab pegol) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023


Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

UCB’s Cimzia is a pegylated Fab fragment of a humanized anti-TNF IgG molecule, and is indicated for the treatment of adult patients with moderate to severe RA. It is self-administered once every two or four weeks by SC injection. Cimzia dampens the inflammatory process, reducing the rate of progressive joint damage, thus improving physical function. Cimzia is a small antibody, with a mass of about 40kDa (kilodaltons); therefore, it lacks the ability to cross-link, and it also lacks an Fc region. Clinical evidence suggests that Cimzia has an efficacy and safety profile similar to other TNF inhibitors, which may be attributable to its ability to penetrate inflamed joints more efficiently due to its small size. Cimzia is also indicated for Crohn’s disease, psoriatic arthritis, axial spondyloarthritis, and ankylosing spondylitis.


- Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Cimzia including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Cimzia for the top nine countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and China.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Cimzia performance.
- Obtain sales forecast for Cimzia from 2013-2023 in top nine countries (the US, France, Germany, Italy, Spain, the UK and Japan, Australia and China).

Table Of Contents

Cimzia (certolizumab pegol) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023
1 Table of Contents
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 13
3 Disease Overview 14
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 14
3.2 Symptoms 18
3.3 Prognosis 19
3.4 Quality of Life 19
4 Disease Management 20
4.1 Diagnosis and Treatment Overview 20
4.1.1 Diagnosis 20
4.1.2 Treatment Guidelines 22
4.1.3 Leading Prescribed Drugs for the Treatment of RA 32
4.1.4 Clinical Practice 34
5 Competitive Assessment 39
5.1 Overview 39
6 Cimzia (certolizumab pegol) 41
6.1 Overview 41
6.2 Efficacy 43
6.3 Safety 43
6.4 SWOT Analysis 44
6.5 Forecast 45
7 Appendix 46
7.1 Bibliography 46
7.2 Abbreviations 49
7.3 Methodology 52
7.4 Forecasting Methodology 52
7.4.1 Diagnosed RA Patients 52
7.4.2 Percentage of Drug-Treated Patients 53
7.4.3 General Pricing Assumptions 53
7.4.4 Individual Drug Assumptions 54
7.4.5 Generic and Biosimilar Erosion 54
7.5 Primary Research - KOLs Interviewed for This Report 55
7.6 Primary Research - Prescriber Survey 57
7.7 About the Authors 58
7.7.1 Analyst 58
7.7.2 Reviewer 58
7.7.3 Therapy Area Director 59
7.7.4 Global Head of Healthcare 59
7.8 About GlobalData 60
7.9 Disclaimer 60

1.1 List of Tables

Table 1: Symptoms of RA 18
Table 2: 1987 ACR Diagnostic Criteria for RA 21
Table 3: 2010 ACR/EULAR Diagnostic Criteria for RA 22
Table 4: Treatment Guidelines for RA Used by Each Country in the 10MM 25
Table 5: ACR 2012 Criteria for RA Remission and Low/Moderate/High Disease Activity 28
Table 6: EULAR 2013 Criteria for RA Remission 29
Table 7: Most Prescribed Biologics for RA (After csDMARDs) in the Global Markets, 2014 33
Table 8: Leading Branded Treatments for RA 2014 40
Table 9: Product Profile - Cimzia 42
Table 10: Cimzia SWOT Analysis, 2014 44
Table 11: Global Sales Forecasts ($m) for Cimzia, 2013-2023 45
Table 12: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 57

1.2 List of Figures

Figure 1: Normal Synovial Joint and Synovial Joint with RA 15
Figure 2: Cellular and Cytokine Targets for the Current RA Drugs 17
Figure 3: Disease Management Flowchart for Early RA - ACR 2012 29
Figure 4: Disease Management Flowchart for Established RA - ACR 2012 30
Figure 5: Flowchart for the Management of RA - EULAR 2013 31

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hepatitis C: KOL Insight

Hepatitis C: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

As hepatitis C cures multiply, how do experts evaluate the options? Since the launch of Sovaldi (sofosbuvir; Gilead) in 2013, the hepatitis C (HCV) landscape has developed at a rapid pace. The focus ...

Chronic Lymphocytic Leukaemia: KOL Insight

Chronic Lymphocytic Leukaemia: KOL Insight

  • $ 8085
  • Industry report
  • August 2016
  • by Firstword Pharma

How will established and emerging agents reshape the CLL treatment landscape? How do key opinion leaders (KOLs) see the future treatment paradigm for chronic lymphocytic leukaemia (CLL) shaping up? Will ...

Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.